** WuXi XDC Cayman 2268.HK rises 4.4% to HK$30.75; set for a second straight session of gains

** Chinese antibody drug developer sees 2024 rev, net profit and adjusted net profit jumping more than 85%, 260% and 170% y/y, respectively, on demand from antibody drug conjugate and bioconjugate industries

** Profit margin improving on high utilisation rate of co's production facilities; faster ramp-up of production lines also increases operating efficiency

** Stock third biggest pct gainer on Hong Kong's healthcare index .HSCIH, which is down 0.7%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))